CNBM Affirms No Group‐Level Impact After Subsidiary Tianshan Material Restates Prior‐Period Results

Bulletin Express
03/31

China National Building Material Company Limited (CNBM) reported that its Shenzhen-listed subsidiary, Tianshan Material Co., Ltd., has retrospectively corrected accounting errors related to asset disposal gains booked in 2024. The revisions stem from an erroneous interpretation of Chinese Accounting Standards by Jiangshan Southern Cement, a Tianshan Material subsidiary, when recognising gains from a resumption agreement signed in December 2024.

Key restatement effects on Tianshan Material’s consolidated statements are as follows:

• FY 2024: total assets down by RMB139.47 million, total liabilities down by RMB19.94 million, owners’ equity down by RMB119.53 million, and net profit attributable to owners down by RMB119.53 million.

• Q1 2025 and H1 2025: total assets up by RMB8.13 million, total liabilities up by RMB129.92 million, owners’ equity down by RMB121.79 million, and net profit attributable to owners down by RMB2.25 million in each period.

• Q3 2025: total assets up by RMB1.12 million, owners’ equity up by RMB1.12 million, and net profit attributable to owners up by RMB120.66 million.

Da Hua Certified Public Accountants (Special General Partnership) has issued a special assurance report confirming that the adjustments comply with Chinese Accounting Standards.

CNBM stated that, after consulting its auditors, the restatement does not materially affect the group’s audited consolidated financial statements under IFRS for the year ended 31 December 2024, nor its previously released interim financials for 2025. Consequently, no amendments to CNBM’s published accounts are required at this stage.

The group indicated that any further relevant information will be disclosed in accordance with Hong Kong listing rules and other applicable regulations.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10